{
    "Clinical Trial ID": "NCT01575522",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Treatment (Tivantinib)",
        "  Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Tivantinib: Given PO"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Participants must have histologically or cytologically confirmed invasive breast cancer, with recurrent or metastatic disease; participants without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation",
        "  Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan",
        "  Participants must have recent evidence of progressive disease",
        "  Participants must have received 1-3 prior chemotherapeutic regimens for metastatic breast cancer and must have been off treatment with chemotherapy for at least 14 days before enrollment in the study",
        "  Participants must have discontinued all biologic therapy (including vaccines) at least 14 days before enrollment in the study",
        "  Participants must have discontinued any investigational therapy at least 14 days before enrollment in the study",
        "  Participants may have received prior radiation therapy in either the metastatic or early-stage setting",
        "  Radiation therapy must be completed at least 14 days before enrollment in the study",
        "  Participant must not have received radiation to > 25% of his or her bone marrow within 30 days of starting study treatment",
        "  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)",
        "  Hemoglobin >= 9.0 g/dL",
        "  Absolute neutrophil count >= 1,500/mcL",
        "  Platelets >= 100,000/mcL",
        "  Total bilirubin =< 1.5 times upper limit of normal (ULN)",
        "  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 times institutional ULN; for participants with documented liver metastases, AST/ALT =< 5.0 times ULN",
        "  Serum creatinine =< 1.5 times ULN OR creatinine clearance >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal",
        "  Either the primary tumor and/or the metastasis must be triple-negative; the invasive tumor must be hormone-receptor poor, defined as estrogen-receptor negative (ER-) and progesterone-receptor negative (PR-), or staining < 10% by immunohistochemistry (IHC)",
        "  Human epidermal growth factor receptor 2 (HER2) status: the invasive tumor must be HER2-negative, defined as 0 or 1+ by IHC, or FISH < 2.0",
        "  Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the study and for 90 days after the last investigational drug dose received",
        "  Female subjects of childbearing potential must have a negative serum pregnancy test within 21 days of cycle 1 day 1",
        "  Participants on bisphosphonates may continue receiving bisphosphonate therapy during study treatment; bisphosphonate therapy may also be initiated on study treatment if needed",
        "  Confirmed availability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue",
        "  Ability to understand and the willingness to sign a written informed consent document",
        "Exclusion Criteria:",
        "  Participants who have received chemotherapy, biologic, investigational, or radiotherapy within 14 days prior to entering the study",
        "  Participants who are receiving any other investigational agents",
        "  Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms",
        "  Participants with a history of treated central nervous system (CNS) metastases are eligible",
        "  Treated brain metastases are defined as those having no evidence of progression or hemorrhage for >= 2 months after treatment, and no ongoing requirement for corticosteroids, as ascertained by clinical examination and brain imaging (magnetic resonance imaging or computed tomography [CT] scan) during the screening period",
        "  Treatment for brain metastases may include whole-brain radiotherapy, radiosurgery, or a combination as deemed appropriate by the treating physician",
        "  Participants may be taking anti-convulsant medications, which must be non-enzyme-inducing anti-epileptic drugs",
        "  History of allergic reactions attributed to compounds of similar chemical or biologic composition to ARQ 197",
        "  History of congestive heart failure defined as Class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); clinically significant bradycardia or other uncontrolled, cardiac arrhythmia defined as >= grade 3 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, or uncontrolled hypertension; myocardial infarction occurring within 6 months prior to study entry (myocardial infarction occurring > 6 months prior to study entry is permitted)",
        "  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements",
        "  Pregnant women are excluded from this study",
        "  Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  PFS Status",
        "  Analyzed using the Kaplan-Meier method. 95% confidence intervals (CI) will be determined. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.",
        "  Time frame: Time from start of treatment to time of progression or death, assessed up to 6 months",
        "Results 1: ",
        "  Arm/Group Title: Treatment (Tivantinib)",
        "  Arm/Group Description: Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Tivantinib: Given PO",
        "  Overall Number of Participants Analyzed: 22",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  1.2        (1.0 to 1.4)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 13/22 (59.09%)",
        "  Constipation 1/22 (4.55%)",
        "  Death  [1]3/22 (13.64%)",
        "  Neutropenia 1/22 (4.55%)",
        "  Anxiety 1/22 (4.55%)",
        "  Pleural effusion 1/22 (4.55%)",
        "  Cough 1/22 (4.55%)",
        "  Dyspnea 3/22 (13.64%)",
        "  Cellulitis 1/22 (4.55%)",
        "  Thromboembolic event 1/22 (4.55%)"
    ]
}